Research Resources
Source-checked guides to GLP-1 labels, trials, and peptide research.
Educational only — not medical advice.
Practical Guides
GLP-1 pharmacokinetics
Semaglutide & tirzepatide half-life
Read the current labels’ peak-time, half-life, and steady-state facts—and what a modeled level curve cannot measure or predict.
GLP-1 label guide
GLP-1 medications and birth control
What the current Mounjaro, Zepbound, Ozempic, and Wegovy labels say about oral contraceptives and pregnancy planning.
GLP-1 label guide
Wegovy & Zepbound thyroid monitoring
Separate routine monitoring from label language about an already-observed calcitonin result or thyroid nodule.
Working with your prescriber
Build a medication & peptide protocol history
Organize a current product snapshot and dated change log for a clearer, source-checked prescriber handoff.
GLP-1 evidence guide
Semaglutide and diabetic retinopathy
Separate the Ozempic label signal from the post-hoc SUSTAIN 6 explanation—and keep a neutral care-team record.
GLP-1 biomarker guide
Amylase, lipase, and pancreatitis
See what current labels report, why one elevated result is not a diagnosis, and what context to preserve for a clinician.
GLP-1 label guide
GLP-1 medicines and gallbladder risk
Compare the exact Wegovy and Zepbound label incidences, understand the weight-loss evidence boundary, and build a neutral event timeline.
Multi-compound tracking
Keep a multi-compound protocol timeline legible
Use a current roster, dated event timeline, and unresolved-question queue without turning a tracker into an interaction screen.
Study Teardowns
Study teardown
Does Wegovy (semaglutide) protect your heart without diabetes? If you already have heart disease, yes
6.5% vs 8.0% had a heart attack, stroke or cardiovascular death in Novo Nordisk’s 17,604-person SELECT trial. Absolute risk, who was studied, who paid, and side-effect dropouts, with charts from the published numbers.
Study teardown
How much weight will you lose on Zepbound or Mounjaro (tirzepatide)? About 15–21%
Three doses vs placebo over 72 weeks in Eli Lilly’s main weight-loss trial (SURMOUNT-1), side effects in absolute terms, who ran it, and regain after stopping, with charts rebuilt from the published numbers.
Study teardown
How much weight will you lose on Wegovy (semaglutide)? About 15%, and most came back after stopping
What the placebo group got, who ran Novo Nordisk’s main weight-loss trial (STEP 1), dropouts, absolute effects, and regain after stopping, with charts rebuilt from the published numbers.